Lamivudine therapy in renal allograft recipients with hepatitis B virus infection.
Tsang
W K
WK
Division of Nephrology, Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong, China.
Tong
K L
KL
Chan
H W H
HW
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000502:physiology*; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D011183:Postoperative Complications / Q000821:virology; D012008:Recurrence; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014775:Virus Activation
D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D007166:Immunosuppressive Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine